Interleukin-13 Treatment of Living Lung Tissue Model Alters the Metabolome and Proteome—A Nano-DESI MS Metabolomics and Shotgun Proteomics Study
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25095034 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Gábor Tóth und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry-BMC, Uppsala University, 75237 Uppsala, Sweden. Hauptthemen laut MEDLINE: Interleukin-13, Lung, Proteomics, Metabolomics. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Swedish Research Council, VINNOVA.
Abstract (Originalsprache)
Asthma is a chronic respiratory disease with one of the largest numbers of cases in the world; thus, constant investigation and technical development are needed to unravel the underlying biochemical mechanisms. In this study, we aimed to develop a nano-DESI MS method for the in vivo characterization of the cellular metabolome. Using air–liquid interface (ALI) cell layers, we studied the role of Interleukin-13 (IL-13) on differentiated lung epithelial cells acting as a lung tissue model. We demonstrate the feasibility of nano-DESI MS for the in vivo monitoring of basal–apical molecular transport, and the subsequent endogenous metabolic response, for the first time. Conserving the integrity of the ALI lung-cell layer enabled us to perform temporally resolved metabolomic characterization followed by “bottom-up” proteomics on the same population of cells. Metabolic remodeling was observed upon histamine and corticosteroid treatment of the IL-13-exposed lung cell monolayers, in correlation with alterations in the proteomic profile. This proof of principle study demonstrates the utility of in vivo nano-DESI MS for characterizing ALI tissue layers, and the new markers identified in our study provide a good starting point for future, larger-scale studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry-BMC, Uppsala University, 75237 Uppsala, Sweden.
- AstraZeneca R&D, 43183 Mölndal, Sweden.
ORCID-Profile: Ingela Lanekoff
Förderung
- European Research Council
- Swedish Research Council
- VINNOVA
- European Union
Zitieren
APA
Tóth, G., Golubova, A., Falk, A., Lind, S. B., Nicholas, M., & Lanekoff, I. (2024). Interleukin-13 Treatment of Living Lung Tissue Model Alters the Metabolome and Proteome—A Nano-DESI MS Metabolomics and Shotgun Proteomics Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25095034
Vancouver
Tóth G, Golubova A, Falk A, Lind SB, Nicholas M, Lanekoff I. Interleukin-13 Treatment of Living Lung Tissue Model Alters the Metabolome and Proteome—A Nano-DESI MS Metabolomics and Shotgun Proteomics Study. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25095034
BibTeX
@article{Tth2024,
author = {Tóth, Gábor and Golubova, Anastasia and Falk, Alexander and Lind, Sara Bergström and Nicholas, Mark and Lanekoff, Ingela},
title = {Interleukin-13 Treatment of Living Lung Tissue Model Alters the Metabolome and Proteome—A Nano-DESI MS Metabolomics and Shotgun Proteomics Study},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25095034}
}
EUVIMED